Double maintains 2 strategies that include ELVN - Enliven Therapeutics, Inc.
Yahoo
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
Yahoo
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update, including highlights of pipeline progress.
Finnhub
Enliven Therapeutics Inc: * ENLIVEN THERAPEUTICS Q4 OPERATING EXPENSES USD 26.896MILLION * ENLIVEN THERAPEUTICS Q4 NET INCOME USD -23.18 MILLION * ENLIVEN...
Yahoo
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m. ET.
Yahoo
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Yahoo
Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway. "It's a little bit of optics right now," Goldstein explains. "Clearly, any disruption is typically bad unless it involves dismantling regulation, so the surprise announcement that all of a sudden all federal grants will be frozen — you have to take a sort of a bit of a knee-jerk reaction." "The reality is, for the biotech industry, while research is the lifeblood of this industry, a lot of the research is being federally funded ... there are labs that are being funded that are working with biotech and pharmaceutical companies, or clinical trials that are being funded through federal grants that are being run through big hospital administrations," she explains, adding, "It just adds a layer of uncertainty." Additionally, Goldstein notes that it is currently unclear how the biotech sector could be impacted if Robert F. Kennedy Jr. gets confirmed as Secretary of Health and Human Services (HHS), who fielded questions from the Senate Finance Committee as part of his confirmation hearing Thursday. "We're walking a bit of a tightrope to some degree ... you have some nominees that are not necessarily science-friendly but maybe are friendlier from a regulatory perspective." She adds that looser antitrust regulation expected under Trump could also benefit the biotech industry. Goldstein highlights Enliven Therapeutics (ELVN), Protagonist (PTGX), and Delcath (DCTH) as top biotech picks. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Naomi Buchanan.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HLN | 0.04% | $45.90B | +23.30% | 0.50% |
CMS | -0.04% | $22.33B | +25.86% | 2.76% |
VHC | 0.05% | $35.77M | +37.68% | 0.00% |
CVGW | 0.05% | $419.34M | -9.89% | 2.98% |
NOMD | 0.07% | $3.02B | +4.08% | 3.10% |
MRK | 0.11% | $218.76B | -33.33% | 3.60% |
NEUE | -0.14% | $57.12M | +4.27% | 0.00% |
DUK | 0.14% | $93.55B | +25.45% | 3.37% |
TTE | 0.19% | $135.10B | -10.80% | 5.37% |
PULM | 0.22% | $22.13M | +234.81% | 0.00% |
NGL | 0.22% | $615.18M | -18.67% | 0.00% |
YUM | 0.25% | $44.16B | +13.83% | 1.69% |
FLO | 0.40% | $4.00B | -18.06% | 5.03% |
CPSH | 0.42% | $23.10M | -12.15% | 0.00% |
FUBO | 0.43% | $1.08B | +101.92% | 0.00% |
HUSA | 0.45% | $11.76M | -47.55% | 0.00% |
CYCN | -0.47% | $7.07M | -17.41% | 0.00% |
DRVN | 0.52% | $2.84B | +12.92% | 0.00% |
DVA | -0.55% | $12.34B | +14.04% | 0.00% |
ELS | 0.58% | $12.74B | +6.15% | 2.84% |
Current Value
$18.911 Year Return
Current Value
$18.911 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -33.03% | $416.76M | 1.43% |
TAIL | -30.76% | $87.65M | 0.59% |
VIXY | -29.72% | $195.31M | 0.85% |
TOTL | -18.11% | $3.51B | 0.55% |
CCOR | -15.82% | $64.12M | 1.18% |
BSMR | -14.36% | $235.44M | 0.18% |
JMST | -10.28% | $3.54B | 0.18% |
ULST | -8.31% | $585.14M | 0.2% |
SHYD | -7.88% | $319.95M | 0.35% |
DFNM | -7.38% | $1.51B | 0.17% |
CTA | -7.31% | $978.30M | 0.76% |
USDU | -7.22% | $206.96M | 0.5% |
IBTG | -6.61% | $1.82B | 0.07% |
XONE | -6.54% | $631.21M | 0.03% |
DBA | -6.51% | $829.48M | 0.93% |
BSMW | -6.46% | $101.29M | 0.18% |
CGSM | -6.30% | $640.07M | 0.25% |
UNG | -6.30% | $397.59M | 1.06% |
PWZ | -6.06% | $703.30M | 0.28% |
CGMU | -5.81% | $3.01B | 0.27% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
STPZ | <0.01% | $427.83M | 0.2% |
SCHR | 0.01% | $10.47B | 0.03% |
SMB | 0.04% | $265.76M | 0.07% |
MUB | 0.05% | $39.67B | 0.05% |
BKAG | 0.05% | $1.99B | 0% |
IBTO | -0.05% | $334.00M | 0.07% |
NUBD | -0.08% | $412.78M | 0.16% |
VTEB | -0.09% | $36.03B | 0.03% |
UGA | -0.13% | $87.23M | 0.97% |
GCOR | -0.18% | $352.35M | 0.08% |
IBTM | -0.21% | $310.98M | 0.07% |
TYA | -0.22% | $158.79M | 0.15% |
USTB | -0.23% | $1.14B | 0.35% |
CLOA | -0.26% | $783.46M | 0.2% |
IEI | -0.27% | $15.67B | 0.15% |
SPTI | 0.28% | $7.77B | 0.03% |
BSV | -0.30% | $34.47B | 0.03% |
DBE | 0.30% | $55.52M | 0.77% |
IVOL | 0.35% | $476.36M | 1.02% |
SUB | 0.35% | $8.76B | 0.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 53.78% | $4.76B | 0.35% |
GNOM | 49.89% | $47.13M | 0.5% |
RSPA | 49.64% | $292.67M | 0% |
IBB | 47.81% | $5.61B | 0.45% |
IWC | 47.36% | $797.08M | 0.6% |
IWO | 46.83% | $10.72B | 0.24% |
CPRJ | 45.98% | $48.38M | 0.69% |
ARKG | 45.79% | $936.86M | 0.75% |
KJUL | 45.46% | $155.05M | 0.79% |
VTWO | 44.67% | $10.92B | 0.07% |
PTH | 44.60% | $107.91M | 0.6% |
IWM | 44.50% | $62.65B | 0.19% |
VBK | 44.39% | $17.32B | 0.07% |
KOMP | 44.27% | $1.95B | 0.2% |
SCHA | 43.95% | $15.94B | 0.04% |
VXF | 43.88% | $19.92B | 0.05% |
ONLN | 43.87% | $68.06M | 0.58% |
QQA | 43.27% | $187.77M | 0% |
ARKK | 43.11% | $5.03B | 0.75% |
KAPR | 43.11% | $144.85M | 0.79% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
APGE | 46.12% | $2.25B | -36.95% | 0.00% |
CRNX | 45.18% | $2.92B | -34.08% | 0.00% |
DNLI | 45.15% | $2.00B | -29.07% | 0.00% |
CELC | 42.30% | $354.18M | -53.20% | 0.00% |
KYMR | 42.25% | $1.71B | -29.01% | 0.00% |
CLDX | 41.64% | $1.15B | -56.93% | 0.00% |
OCUL | 41.46% | $1.17B | -13.14% | 0.00% |
BPMC | 40.65% | $5.75B | -2.41% | 0.00% |
KRYS | 39.59% | $5.21B | +1.76% | 0.00% |
RVMD | 39.54% | $6.43B | +10.23% | 0.00% |
RCKT | 39.44% | $671.77M | -75.23% | 0.00% |
ATXS | 39.36% | $311.52M | -54.38% | 0.00% |
W | 39.17% | $4.28B | -45.97% | 0.00% |
PLAB | 39.12% | $1.30B | -27.97% | 0.00% |
ACLX | 39.06% | $3.69B | +6.38% | 0.00% |
QTWO | 38.38% | $5.00B | +58.51% | 0.00% |
XPER | 38.24% | $355.04M | -29.60% | 0.00% |
NTLA | 38.12% | $755.67M | -70.78% | 0.00% |
BHE | 38.11% | $1.38B | +27.09% | 2.01% |
QTRX | 37.72% | $260.58M | -69.40% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
GL | -26.80% | $11.08B | +20.01% | 0.75% |
CBOE | -20.34% | $23.50B | +25.53% | 1.05% |
COR | -15.99% | $54.20B | +13.71% | 0.74% |
CHD | -11.53% | $26.66B | +5.00% | 1.03% |
MO | -11.31% | $96.57B | +35.61% | 6.83% |
VSTS | -10.72% | $1.32B | -47.67% | 1.54% |
GIS | -10.68% | $32.41B | -14.20% | 3.90% |
CPB | -10.16% | $11.75B | -8.27% | 3.73% |
MSDL | -10.08% | $1.79B | -4.01% | 9.98% |
CI | -9.48% | $89.99B | -8.07% | 1.68% |
CME | -9.33% | $94.61B | +23.82% | 3.89% |
KMB | -8.92% | $47.39B | +13.36% | 3.37% |
VZ | -8.62% | $188.34B | +4.44% | 5.84% |
PG | -8.49% | $397.45B | +8.55% | 2.32% |
FATBB | -8.17% | $56.94M | -23.78% | 14.95% |
ED | -7.89% | $38.69B | +21.90% | 2.95% |
MCK | -7.76% | $86.92B | +28.41% | 0.38% |
CL | -7.24% | $75.88B | +6.19% | 2.07% |
WBA | -7.15% | $9.67B | -39.57% | 6.80% |
PGR | -6.89% | $164.86B | +33.43% | 1.71% |